Phase 2Heart FailureRecruiting
JK07 — Heart Failure
Heart Failure (across EF ranges)
Protocol: JK07201
About this study
Novel heart failure therapy under investigation across the spectrum of ejection fraction, including HFrEF, HFmrEF, and HFpEF.
Sponsor: JK07 Bio
Key eligibility
- Adults 18–85 with chronic heart failure
- NYHA Class II–III symptoms
- On stable guideline-directed medical therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.